Ozempic
Ozempic Vision Loss Lawsuit Over Alleged NAION Risk From GLP-1 Drugs
A lawsuit alleges Novo Nordisk and Eli Lilly failed to warn of NAION vision loss from Ozempic and Mounjaro. The companies dispute it. Follow the case.
- Potential payment
- Up to $50,000
Subject to eligibility and claim terms.
- Claim deadline
- TBD
- Proof requirement
- TBD
Eligibility
Who may qualify?
Check the covered dates, products, locations, and other official terms before you file.
- You took a GLP-1 medication, and you were diagnosed with NAION or suffered sudden vision loss connected to that medication.
Case overview
What is the Ozempic case about?
A group of federal lawsuits has been consolidated into a single proceeding known as multidistrict litigation, or MDL. Patients bringing the cases allege that popular GLP-1 medications caused a rare and serious eye condition called non-arteritic anterior ischemic optic neuropathy, or NAION, sometimes referred to as an "eye stroke" because it can cause sudden and often permanent vision loss in one eye.
At the center of the litigation is the claim that drug makers failed to adequately warn patients and doctors of this risk. The companies deny wrongdoing and are fighting the allegations. No court has ruled on the claims, and whether these drugs actually cause NAION remains a matter of ongoing scientific debate.
Case details
- Company
- Novo Nordisk, Eli Lilly
Questions people ask
Frequently asked questions
How much is the Ozempic case payout?
The listed potential payment is Up to $50,000. Final amounts depend on the number of valid claims and the administrator's terms.
Who qualifies for the Ozempic case?
Key eligibility criteria include: You took a GLP-1 medication, and you were diagnosed with NAION or suffered sudden vision loss connected to that medication. Always confirm the full class definition with the official source before filing.
Is the Ozempic case open for claims?
Not yet. No claim process is currently open. TapClaim monitors official updates to this case.
Settlement administrator and official sources
- Listing verificationLast checked Sep 26, 2026
